Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

# oncology

Trending Latest

Mashup Score:37

ascopost.com

FDA Approves Sacituzumab Govitecan-hziy for Pretreated Patients With HR-Positive, HER2-Negative Breast Cancer – The ASCO Post - 4 days

Mashup Score:37

By The ASCO Post Staff Posted: 2/3/2023 12:22:00 PM Last Updated: 2/3/2023 12:39:23 PM On February 3, the U.S. Food and Drug Administration (FDA)...

More coverage: #bcsm #breastcancer #oncology
See more from

Mashup Score:18

OncLive

FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2– Metastatic Breast Cancer - 4 days

Mashup Score:18

The FDA has approved sacituzumab govitecan-hziy (Trodelvy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer...

More coverage: #bcsm #oncology
See more from

Mashup Score:14

Esmo Open

Precision medicine in early breast cancer—beginning of a successful story? - 1 week

Mashup Score:14

Over the past 20 years, advances in genomic characterization of breast cancer enabled the constant evolution of clinically relevant subtypes from immunohistochemically defined groups,...

More coverage: #breastcancer #oncology #precision
See more from

Mashup Score:12

OncLive

Adjuvant T-DM1 Plus Concurrent Radiation Not Associated With Increased Cardiotoxicity in HER2+ Breast Cancer - 2 days

Mashup Score:12

Mridula George, MD, discusses the methods used to evaluate cardiotoxicity associated with adjuvant trastuzumab emtansine plus concurrent radiation therapy, and explains implications on the...

More coverage: #bcsm #oncology
See more from

Mashup Score:9

OncLive

Immunotherapy Propels Urothelial Carcinoma Treatment Advances - 5 days

Mashup Score:9

Stephanie A. Berg, DO, discussed the implications of these findings on the urothelial cancer treatment paradigm and how updated results may further influence the...

More coverage: #medtwitter #oncology
See more from

Mashup Score:8

UROonco23

What to expect at the first-ever UROonco23? – UROonco23 - 4 days

Mashup Score:8

Join the first European onco-urology event, UROonco23 in Gothenburg, Sweden from June 30 to July 2, 2023. Get updates on genitourinary (GU) cancers from...

More coverage: #bladdercancer #oncology #prostatecancer #rcc #uroonco
See more from

Mashup Score:8

ascopost.com

Filippo Pietrantonio on Gastric or Gastroesophageal Junction Adenocarcinoma Recent Data on Treatment With Tremelimumab and Durvalumab – The ASCO Post - 1 week

Mashup Score:8

2023 ASCO Gastrointestinal Cancers Symposium Filippo Pietrantonio, MD, of Italy’s Istituto Nazionale dei Tumori, discusses phase II results from the INFINITY trial of tremelimumab...

More coverage: #gastriccancer #gejcancer #gi23 #oncology #stcsm
See more from

Mashup Score:8

OncLive

Neoadjuvant Pembrolizumab Elicits Deep Responses in Localized MSI-H/dMMR Solid Tumors - 1 week

Mashup Score:8

Neoadjuvant pembrolizumab was found to have high clinical activity and an acceptable safety profile in patients with localized microsatellite instability–high/deficient mismatch repair solid...

More coverage: #medtwitter #oncology
See more from

Mashup Score:8

OncLive

KEYNOTE-991 Trial of Pembrolizumab Plus Enzalutamide/ADT in mHSPC to Stop for Futility - 1 week

Mashup Score:8

Merck is discontinuing the phase 3 KEYNOTE-991 trial evaluating pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide/ADT in patients with metastatic...

More coverage: #oncology #pcsm
See more from

Mashup Score:8

OncLive

Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC - 2 days

Mashup Score:8

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations,...

More coverage: #oncology #pcsm
See more from
Load More